438 related articles for article (PubMed ID: 17520866)
1. Cannabinoids for the treatment of inflammation.
Ashton JC
Curr Opin Investig Drugs; 2007 May; 8(5):373-84. PubMed ID: 17520866
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of cannabinoid receptor ligands: current status.
Singh J; Budhiraja S
Methods Find Exp Clin Pharmacol; 2006 Apr; 28(3):177-83. PubMed ID: 16810344
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology of cannabinoids.
Grotenhermen F
Neuro Endocrinol Lett; 2004; 25(1-2):14-23. PubMed ID: 15159677
[TBL] [Abstract][Full Text] [Related]
4. Effect of CP55,940 on mechanosensory spinal neurons following chronic inflammation.
Choong KC; Su X; Urban MO
Neurosci Lett; 2007 Mar; 414(2):105-9. PubMed ID: 17194542
[TBL] [Abstract][Full Text] [Related]
5. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures--a short review.
Svízenská I; Dubový P; Sulcová A
Pharmacol Biochem Behav; 2008 Oct; 90(4):501-11. PubMed ID: 18584858
[TBL] [Abstract][Full Text] [Related]
6. The pharmacology of cannabinoid receptors and their ligands: an overview.
Pertwee RG
Int J Obes (Lond); 2006 Apr; 30 Suppl 1():S13-8. PubMed ID: 16570099
[TBL] [Abstract][Full Text] [Related]
7. Beneficial effects of cannabinoids (CB) in a murine model of allergen-induced airway inflammation: role of CB1/CB2 receptors.
Braun A; Engel T; Aguilar-Pimentel JA; Zimmer A; Jakob T; Behrendt H; Mempel M
Immunobiology; 2011 Apr; 216(4):466-76. PubMed ID: 21056512
[TBL] [Abstract][Full Text] [Related]
8. Cannabinoids and the skeleton: from marijuana to reversal of bone loss.
Bab I; Zimmer A; Melamed E
Ann Med; 2009; 41(8):560-7. PubMed ID: 19634029
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2.
McHugh D; Tanner C; Mechoulam R; Pertwee RG; Ross RA
Mol Pharmacol; 2008 Feb; 73(2):441-50. PubMed ID: 17965195
[TBL] [Abstract][Full Text] [Related]
10. Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide.
Loría F; Petrosino S; Mestre L; Spagnolo A; Correa F; Hernangómez M; Guaza C; Di Marzo V; Docagne F
Eur J Neurosci; 2008 Aug; 28(4):633-41. PubMed ID: 18657182
[TBL] [Abstract][Full Text] [Related]
11. Latest advances in cannabinoid receptor agonists.
Thakur GA; Tichkule R; Bajaj S; Makriyannis A
Expert Opin Ther Pat; 2009 Dec; 19(12):1647-73. PubMed ID: 19939187
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of selective cannabinoid CB(1) and CB(2) receptor agonists in a mouse model of lipopolysaccharide-induced interstitial cystitis.
Tambaro S; Casu MA; Mastinu A; Lazzari P
Eur J Pharmacol; 2014 Apr; 729():67-74. PubMed ID: 24561047
[TBL] [Abstract][Full Text] [Related]
13. Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
Lin LS; Lanza TJ; Jewell JP; Liu P; Shah SK; Qi H; Tong X; Wang J; Xu SS; Fong TM; Shen CP; Lao J; Xiao JC; Shearman LP; Stribling DS; Rosko K; Strack A; Marsh DJ; Feng Y; Kumar S; Samuel K; Yin W; Van der Ploeg LH; Goulet MT; Hagmann WK
J Med Chem; 2006 Dec; 49(26):7584-7. PubMed ID: 17181138
[TBL] [Abstract][Full Text] [Related]
14. Basic neuroanatomy and neuropharmacology of cannabinoids.
Breivogel CS; Sim-Selley LJ
Int Rev Psychiatry; 2009 Apr; 21(2):113-21. PubMed ID: 19367505
[TBL] [Abstract][Full Text] [Related]
15. Excitotoxicity in a chronic model of multiple sclerosis: Neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation.
Docagne F; Muñetón V; Clemente D; Ali C; Loría F; Correa F; Hernangómez M; Mestre L; Vivien D; Guaza C
Mol Cell Neurosci; 2007 Apr; 34(4):551-61. PubMed ID: 17229577
[TBL] [Abstract][Full Text] [Related]
16. Gut feelings about the endocannabinoid system.
Di Marzo V; Piscitelli F
Neurogastroenterol Motil; 2011 May; 23(5):391-8. PubMed ID: 21481098
[TBL] [Abstract][Full Text] [Related]
17. Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.
Davis MP
Expert Opin Investig Drugs; 2014 Aug; 23(8):1123-40. PubMed ID: 24836296
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a novel class of selective human CB1 inverse agonists.
Foloppe N; Allen NH; Bentley CH; Brooks TD; Kennett G; Knight AR; Leonardi S; Misra A; Monck NJ; Sellwood DM
Bioorg Med Chem Lett; 2008 Feb; 18(3):1199-206. PubMed ID: 18083560
[TBL] [Abstract][Full Text] [Related]
19. Role of CB2 receptors in neuroprotective effects of cannabinoids.
Fernández-Ruiz J; Pazos MR; García-Arencibia M; Sagredo O; Ramos JA
Mol Cell Endocrinol; 2008 Apr; 286(1-2 Suppl 1):S91-6. PubMed ID: 18291574
[TBL] [Abstract][Full Text] [Related]
20. Antinociceptive effects of the non-selective cannabinoid receptor agonist CP 55,940 are absent in CB1(-/-) and not CB2(-/-) mice in models of acute and persistent pain.
Sain NM; Liang A; Kane SA; Urban MO
Neuropharmacology; 2009 Sep; 57(3):235-41. PubMed ID: 19538975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
